Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis With Prior exposure to JAK1/2 Inhibitors

The impact of JAK1/2 inhibitor therapy prior to allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Biol Blood Marrow Transplant
Glavni autori: Shanavas, Mohamed, Popat, Uday, Michaelis, Laura C, Fauble, Veena, McLornan, Donal, Klisovic, Rebecca, Mascarenhas, John, Tamari, Roni, Arcasoy, Murat O, Davies, James, Gergis, Usama, Ukaegbu, Oluchi C, Kamble, Rammurti T, Storring, John M, Majhail, Navneet S, Romee, Rizwan, Verstovsek, Srdan, Pagliuca, Antonio, Vasu, Sumithira, Ernst, Brenda, Atenafu, Eshetu G, Hanif, Ahmad, Champlin, Richard, Hari, Paremeswaran, Gupta, Vikas
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5030817/
https://ncbi.nlm.nih.gov/pubmed/26493563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.10.005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items